Search results (66)
« Back to NewsOxford vaccine against deadly Nipah virus granted EMA PRIME designation for the first time
9 June 2025
The University of Oxford’s vaccine to protect people from deadly Nipah virus has been granted support from the PRIority MEdicines (PRIME) scheme offered by Europe’s medicines regulator, the European Medicines Agency (EMA). It is the first UK academic institution to be awarded this designation.
New MenB Vaccine Shows Promise in Early-Stage Trial Results
19 May 2025
The outcome of a trial published in Science Translational Medicine, shows encouraging results for a new vaccine targeting group B meningococcus (MenB), a significant cause of meningococcal disease worldwide, and establishes proof-of-concept in humans that a gene-based vaccine platform can induce protective antibody responses against bacteria.
Study shows urgent change needed to reduce deaths from malaria and meningitis in comatose African children
28 April 2025
Results of two parallel studies show that one in four African children hospitalised with malaria and coma have an additional infection, and that giving antibiotics with antimalarials could help reduce death rates of comatose children.
Oxford Vaccine Group Launches Novel Study on Relapsing Malaria
22 January 2025
The Oxford Vaccine Group has launched a novel clinical study, BIO-006, to investigate relapsing malaria infections caused by Plasmodium vivax. This unique parasite can remain dormant in the liver for months or years, reactivating to cause repeated malaria infections.
Oxford Vaccine Group Launches Study to Test Paratyphoid A Vaccine
15 January 2025
The Oxford Vaccine Group has launched a new clinical study, BiVISTA, to evaluate an experimental combination vaccine aimed at preventing enteric fever a disease caused by two different types of Salmonella bacteria, typhoid and paratyphoid.
Typhoid vaccine trial confirms sustained protection for older children
10 October 2024
A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.
Ground-breaking research revealed in new video
17 September 2024
The Oxford Vaccine Group has released new footage of ground-breaking research aimed at revolutionising vaccine design, particularly for those most vulnerable to diseases like flu and COVID-19.
Oxford scientists launch first-in-human vaccine trial for deadly Marburg virus
12 July 2024
Scientists at the University of Oxford have launched a new clinical trial to test a vaccine to protect people against deadly Marburg virus.
Professor Teresa Lambe OBE elected to the Fellowship of the Academy of Medical Sciences
21 May 2024
Professor Teresa Lambe OBE, Calleva Head of Immunology at the Oxford Vaccine Group, and Principal Investigator at the Pandemic Sciences Institute, has been elected a Fellow of the Academy of Medical Sciences, one of the most prestigious awards in the field.
Professor Sir Andrew Pollard elected to the Fellowship of the Royal Society
16 May 2024
Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group at the Department of Paediatrics, and Ashall Professor of Infection and Immunity has today been elected a Fellow of the Royal Society.
Ground-breaking study reveals how COVID-19 vaccines prevent severe disease
3 May 2024
A landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.
New trial to study how the human immune system adapts to ‘tolerate’ malaria parasites
18 March 2024
Scientists at the University of Oxford and the University of Edinburgh have launched a pioneering study that examines how the immune system responds to repeated malaria infections. The BIO-004 study is being run in partnership between the Department of Biochemistry (Draper Lab, based in the Kavli Institute for Nanoscience Discovery), the University of Edinburgh (Spence Lab, Institute of Immunology and Infection Research) and the Oxford Vaccine Group (part of the Department of Paediatrics). BIO-004 will provide a unique insight into how the immune system adapts over the first few malaria infections of life, learning to tolerate malaria parasites and developing natural immunity to severe illness.
Oxford University Professors to lecture on new course in 'Translational Science' at three Brazilian institutions
1 February 2024
The Department of Paediatrics at the University of Oxford, has entered into an agreement with three Brazilian Universities, to contribute to the delivery of an undergraduate course in ‘Translational Science’, starting in 2024.
FCDO Minister meets with vaccine researchers
25 January 2024
Researchers from the Department of Paediatrics today welcomed the Rt Hon Andrew Mitchell MP, Minister for Development and Africa, to the laboratories and clinics of several of its vaccine development groups.
First in-human vaccine trial for Nipah virus
11 January 2024
The University of Oxford has launched a new clinical trial to test a vaccine against the deadly Nipah virus.
Oxford Vaccine Group receives £7.8 million in research funding to fight pandemic and epidemic threats
12 December 2023
Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of £7,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential.
OVG Researcher awarded prestigious NIHR Professorship
20 November 2023
Daniela Ferreira, Professor of Respiratory Infection and Vaccinology at the University of Oxford’s Department of Paediatrics and the Department of Clinical Sciences at the Liverpool School of Tropical Medicine has been awarded one of six prestigious Research Professorships by the National Institute of Health and Care Research (NIHR).
CEPI funding announced for development of vaccine prototype
2 November 2023
The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced the launch of a new project to initiate early development of prototype vaccines against the Junín virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly haemorrhagic fevers with epidemic and pandemic potential.
Oxford launches new vaccine trial to enhance design of flu & COVID-19 vaccines
25 October 2023
A pioneering study into human immunity is being launched today by Oxford Vaccine Group at the University of Oxford. The study, called LEGACY03, is being funded by the Medical Research Council part of UK Research and Innovation. By investigating how lymph nodes work, and how they make responses to vaccines in younger and older people, it has the potential to improve vaccine design for different age groups significantly.
First vaccine trial in older people launched for Middle East Respiratory Syndrome (MERS)
18 September 2023
Researchers at the University of Oxford's Pandemic Sciences Institute have launched a new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS).